Freely suspended liposomes are widely used as model membranes for studying lipid-lipid and protein-lipid interactions. Liposomes prepared by conventional methods have chemically identical bilayer leaflets. By contrast, living cells actively maintain different lipid compositions in the two leaflets of the plasma membrane, resulting in asymmetric membrane properties that are critical for normal cell function. Here, we present a protocol for the preparation of unilamellar asymmetric phospholipid vesicles that better mimic biological membranes. Asymmetry is generated by methyl-β-cyclodextrin-catalyzed exchange of the outer leaflet lipids between vesicle pools of differing lipid composition. Lipid destined for the outer leaflet of the asymmetric vesicles is provided by heavy-donor multilamellar vesicles containing a dense sucrose core. Donor lipid is exchanged into extruded unilamellar acceptor vesicles that lack the sucrose core, facilitating the post-exchange separation of the donor and acceptor pools by centrifugation because of differences in vesicle size and density. We present two complementary assays allowing quantification of each leaflet's lipid composition: the overall lipid composition is determined by gas chromatography-mass spectrometry, whereas the lipid distribution between the two leaflets is determined by NMR, using the lanthanide shift reagent Pr
Introduction
The plasma membrane is a marvel of evolutionary nanoengineering. The physical properties of this remarkable organelle are optimized for its dual roles as a cellular barrier and selective gateway. In a sense, these roles are contradictory: the plasma membrane must be sturdy enough to provide protection against an often-harsh external environment, yet malleable enough to allow for cell growth, division, and motility, as well as the passage of water and nutrients. Nature solved this problem with a quasi-two-dimensional fluid formed from a complex mixture of lipid, protein, and carbohydrate. Although its basic architecture is well established, there is an emerging consensus that some critical processes occurring at and within the plasma membrane cannot be adequately explained without invoking nanoscopic membrane structure [1] [2] [3] . This realization has generated renewed interest in the biophysical characterization of membranes at the level of molecular interactions. However, teasing apart these interactions is hardly feasible in a natural plasma membrane that might contain several hundred chemically distinct lipids and thousands of unique proteins. Instead, uncovering the specific interactions that are responsible for functional phenotypes in vivo requires the study of simplified models in vitro, where their composition can be finely controlled.
Lipid bilayer vesicles are among the most widely used model systems for biophysical studies of lipid-lipid and protein-lipid interactions. Conventional liposome preparations created by hydration of a dry lipid film (typically followed by sonication or extrusion to generate unilamellar vesicles) produce bilayers in which the two leaflets have an identical composition. Cellular plasma membranes, on the other hand, actively maintain a different lipid composition in the exofacial (outer) and cytofacial (inner) leaflets 4, 5 . Phosphatidylserine (PS), for instance, is located exclusively in the inner leaflet of the plasma membrane (PM), and its exposure on the outer leaflet serves as a marker of impending cell death in eukaryotes 6 . Mounting evidence suggests that the lipid compositional asymmetry of the PM not only confines certain lipids to their respective leaflets to facilitate their direct interaction with other molecules, but also results in unique membrane properties that, although currently poorly understood, are probably critical for normal cellular function [7] [8] [9] [10] . It follows that symmetric model membranes lack at least some key structural characteristics of natural cell membranes that may critically affect membrane interactions with proteins and small molecules. As such, there is a widely recognized need to expand the biophysical toolkit with model systems that more closely mimic the asymmetric cell membrane environment while still allowing for easily controlled variation of the inner and outer leaflet lipid compositions.
Preparation of asymmetric vesicles
Several techniques exist for preparing asymmetric bilayers 11 . The preparation of asymmetric large unilamellar vesicles (LUVs) is particularly useful because their size is well-defined, and their bilayer properties are not greatly affected by the high curvature found in small unilamellar vesicles (SUVs) or by interactions with a substrate found in supported lipid bilayers.
Although asymmetric giant unilamellar vesicles (GUVs) are not affected by curvature and substrate interaction, their size is harder to control precisely. The main method for preparing asymmetric GUVs of micron size involves passing an inverted emulsion droplet through a lipid-lined oil-water interface 12 , which has the added limitation that the vesicles contain residual organic solvent that could affect the bilayer properties.
The generation of asymmetric LUVs (aLUVs) has been achieved by three different methods: (i) application of a pH differential to vesicles that contain anionic lipids; (ii) external addition of enzymes that selectively modify outer leaflet lipid headgroups; and (iii) external addition of lipid carrier molecules that catalyze intervesicular exchange of the outer leaflet lipids. The pH adjustment method exploits the fact that certain anionic phospholipids (namely, phosphatidylglycerol (PG) and phosphatidic acid (PA)) can rapidly diffuse between bilayer leaflets in their uncharged, protonated form 13 . Applying a pH differential across the bilayer thus induces a redistribution of these lipids, with an accumulation on the more alkaline side 14 . Enzymatic headgroup modification has been used to convert outer leaflet PS to phosphatidylethanolamine (PE), using PS-decarboxylase 15 , or outer leaflet phosphatidylcholine (PC) to either PE or PS, using phospholipase D 16 . In contrast to these methods -each of which acts by chemically modifying a single population of initially symmetric vesiclescatalyzed lipid exchange requires mixing together two symmetric vesicle populations of different composition in the presence of a lipid carrier such as phospholipid-exchange protein 17 , bovine serum albumin 18 , or certain classes of cyclodextrins 19 . We have chosen to use the catalyzed lipid-exchange approach, because of its greater flexibility in comparison with the other methods. The primary disadvantage of catalyzed exchange is that the two vesicle populations must eventually be separated to recover the asymmetric liposomes; below, we describe two different strategies to address this problem. Its primary advantage, however, is its versatility. Although pH adjustment and enzymatic modification are each specific to a subset of phospholipids, catalyzed exchange is compatible with a wide variety of phospholipids and can be used to create asymmetric vesicles with diverse inner and outer leaflet compositions.
Here, we focus on the preparation of aLUVs using catalyzed exchange with methyl-β-cyclodextrin (mβCD) as the lipid carrier. mβCD is a water-soluble, ring-shaped oligosaccharide possessing a hydrophilic outer surface and a central hydrophobic cavity that is large enough to accommodate a lipid chain (Fig. 1a) . The reversible formation of an mβCD-lipid complex effectively displaces water from the cavity, replacing unfavorable interactions with favorable ones 20 . At high concentrations, mβCD will completely dissolve a lipid vesicle suspension, but at lower concentrations, a dynamic equilibrium exists between intact vesicles, mβCD-lipid complexes, and free mβCD 21 . This 'exchange-competent' solution of mβCD and excess donor lipid is the starting point for preparing aLUVs, as shown in Step 1 of Fig. 1b,c . Addition of acceptor LUVs to the mβCD-donor solution results in mβCD-catalyzed exchange of the acceptor vesicles' exposed outer leaflet lipids with the donor lipid pool, while leaving the inner leaflet of the acceptor vesicles relatively unperturbed 19 , as shown in Step 2. Two strategies have been used to separate the original acceptor pool (which contains the aLUVs) from the donor-acceptor-mβCD exchange slurry; each exploits size and/or density differences between the donor and acceptor vesicle pools. The heavy-acceptor strategy (Fig. 1b) makes use of a dense sucrose solution (typically 25% (wt/vol)) trapped in the acceptor vesicle lumen. Donor lipid is typically in the form of multilamellar vesicles (MLVs). MLVs scatter visible light more strongly than LUVs and allow for visual verification that excess donor lipid is present after incubation with mβCD, an important condition for minimizing the loss of acceptor vesicles to dissolution by free cyclodextrin. After exchange, separation is achieved by layering the exchange slurry onto a sucrose solution of intermediate density (typically 10% (wt/vol), although adjustment may be necessary, depending on the density of the donor lipid), followed by ultracentrifugation at 190,000g. The lighter solution, composed primarily of undissolved donor MLVs and mβCD, remains at the top of the centrifuge tube, whereas the heavy-acceptor LUVs sink through the sucrose cushion and are recovered in the pellet, as shown in Fig. 1b, Step 3. The heavy-donor protocol (Fig. 1c) essentially reverses this strategy: the donor lipid film is hydrated in a sucrose solution (typically 20% (wt/wt)) to create large, dense MLVs, whereas the acceptor lipid is hydrated in pure water or buffer. After exchange, the donor MLVs are separated from the lighter, smaller acceptor LUVs by low-speed centrifugation (20,000g) , with the now-asymmetric acceptors recovered in the supernatant, as shown in Fig. 1c, Step 3. Residual mβCD is then removed with a centrifugal ultrafiltration device (Fig. 1c, Step 4). The choice between the two strategies outlined above depends on the details of the specific experiment. The heavy-acceptor protocol simplifies purification of asymmetric vesicles and can minimize donor contamination in cases in which the donor lipid is less dense than the acceptor lipid. However, the sensitivity of follow-up experiments to the presence of sucrose in the asymmetric vesicle core should also be considered. One potential consequence of entrapped sucrose is the introduction of an osmotic stress that can cause bilayer thinning and lipid area expansion 22 . Extruded vesicles are often non-spherical and can easily accommodate small osmotic gradients without accumulating stress by 'rounding up', effectively diluting the internal solution by increasing their volume 23 . Even when accounting for such volume changes, typical experimental conditions-for example, vesicles with a 25% (wt/vol) sucrose core, suspended in PBS buffer-result in a residual osmotic differential of~300 mOsm/kg in aLUVs prepared using the heavy-acceptor strategy. For 100-nm-diameter vesicles, the corresponding tension calculated from Laplace's law is~20 mN/m, a value that can exceed the rupture tension of some lipid bilayers 24 . In cases in which it is desirable to use the heavy-acceptor protocol, the tension can be minimized or eliminated by adjusting the buffer osmolality (e.g., with sucrose) to balance the osmotic pressure. Of course, the osmolyte should be carefully chosen to maintain compatibility with the chosen experimental techniques, as well as to avoid direct interactions with lipids that might alter the membrane properties. The heavy-donor strategy-described in detail in the Procedure below-circumvents these issues and eliminates the need for ultracentrifugation. However, a caveat of the heavy-donor method is that additional purification steps may be required if the donor lipid is less dense than the acceptor lipid, which may result in a reduced yield of the final asymmetric vesicles.
Quantifying leaflet composition
Both the efficiency of outer leaflet exchange and the spontaneous lipid translocation ('flip-flop') rate depend on several factors 25 . For example, the exchange efficiency increases with the ratio of donor-toacceptor lipid used in the preparation and may be influenced nontrivially by preferential interactions between cyclodextrin and the chosen lipids 21 . Lipid flip-flop, although generally much slower than other diffusive lipid motions 26, 27 , depends on the chemical structure of the lipid molecules, including the size and charge of the headgroup 28 and the length and degree of unsaturation of the hydrocarbon chains 29, 30 . It is therefore critical to determine the composition of each bilayer leaflet after the asymmetric liposomes are prepared; it is not safe to assume that the outer leaflet contains only donor lipid or that the inner leaflet contains only acceptor lipid. Quantification of the leaflet composition requires a separate determination of the overall vesicle composition and the asymmetric distribution of each lipid species. The former is generally accomplished with chromatography, for example, thinlayer chromatography (TLC) 19 , gas chromatography (GC) 22 , or ultra-high performance liquid chromatography (UHPLC) 31 . Asymmetry assays generally involve the selective modification, extraction, or interaction of outer leaflet lipids with reagents added externally to the aLUV suspension, followed by detection and quantification; these assays are usually specific to lipid headgroups. Among the methods that have been used to quantify asymmetry are labeling of exposed aminophospholipids (i.e., PS or PE) with trinitrobenzenesulfonic acid (TNBS), followed by TLC 15 ; periodate oxidation of exposed PG, followed by detection of oxidation by-products 13 ; selective outer leaflet extraction of radiolabeled lipids with bovine serum albumin or phospholipid-exchange protein 13 ; binding of a cationic peptide to exposed negatively charged lipids (e.g., PS or PG) 10 ; zetapotential measurements of asymmetric bilayers containing charged lipids 32 ; and hydrolysis of PC by phospholipase D, followed by detection of free choline 16 . In the Procedure, we describe a two-part assay for determining leaflet composition that involves GC-mass spectrometry (MS) (Fig. 2) and NMR (Fig. 3 ). In the first step, GC coupled to MS is used to quantify the total mole fraction of each lipid species. This is done after the aLUV preparation to obtain information about the exchange efficiency (i.e., how much donor lipid was exchanged into the acceptor vesicles). As shown in Fig. 2c , GC is extremely sensitive to even small differences in fatty acid composition (i.e., length and degree of unsaturation) or isotopic content (i.e., protiated versus deuterated chains), making the method ideal for obtaining reliable quantitative information. An alternative technique, UHPLC, can be used instead to determine the overall composition of lipids with the same acyl chains but different headgroups 31 . In the second step, 1 H NMR coupled with a shift reagent is used to determine the asymmetric distribution of lipids with protiated choline headgroups (Fig. 3 ). This assay can distinguish choline headgroups located in the inner leaflets from those located in the outer leaflets because the shift reagent (e.g., a lanthanide ion such as Pr
3+
) is added externally, and it selectively interacts with outer leaflet lipids 22 . Compared with the other asymmetry assays mentioned above, NMR is the most straightforward to implement because the signals from the inner and outer leaflet populations are resolved in a single measurement. The primary limitations of NMR are that (i) it requires that at least one of the lipid components of the aLUV have a choline headgroup (i.e., PC or sphingomyelin (SM)) and (ii) it often fails when aLUVs contain charged lipid in the outer leaflet (in our experience, >10 mol% PG or 2 mol% PS). The latter limitation results from interactions between Pr 3+ and exposed anionic lipid, which can cause liposome aggregation that degrades the NMR signal.
Experimental design
In the Procedure below, we describe the preparation of aLUVs composed of a 1,2-dipalmitoylsn-glycero-3-phosphocholine (DPPC)-enriched outer leaflet and a 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC)-enriched inner leaflet 22, 31 . In principle, the variety of compositions that can be prepared is limited only by the nature of the interaction between mβCD and the different types of lipids. In our own work (summarized in Table 1 ), we have used the protocol to prepare chemically asymmetric vesicles composed of POPC and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE) 33 , DPPC and POPE, egg SM (eSM) and POPE, and 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and POPC, as well as isotopically labeled aLUVs composed of deuterated variants of POPC 22, 33 or DPPC 34 . Some basic sample characterization is an integral part of the protocol. Essential analyses include measuring the vesicle size distribution with dynamic light scattering (DLS) and quantifying the inner and outer leaflet lipid composition (the example described here uses GC and NMR for this purpose, although other assays may be necessary depending on the choice of lipids). There are a few important considerations when modifying the described protocol for a different lipid composition; these are presented below. 
Exchange conditions
The mβCD concentration is carefully chosen to be as high as possible without appreciably dissolving the acceptor vesicles, in order to maximize exchange and yield. Because different lipids interact differently with mβCD 21 , any change in lipid composition should first be examined with dynamic light scattering (DLS) to determine the mβCD concentration at which vesicles begin to rapidly H NMR of SUVs shows distinct inner and outer peaks in the absence of shift reagent. SUVs can be generated by an imbalance in the mβCD/lipid ratio. Adapted from Heberle et al. 22 and Marquardt et al. 34 (original material licensed under Creative Commons Attribution Licenses). Shown are the donor lipid, the acceptor lipid, the donor/acceptor molar ratio, the temperature during mβCD-donor and mβCD-donor-acceptor incubation (Steps 14 and 15 in the Procedure), the mole fractions of donor lipid in the inner (χ D,inner ) and outer (χ D,outer ) leaflets of the aLUVs, the observed exchange efficiency (Eobs), the fraction of donor lipid in the outer leaflet (Dasym), and the respective references.
dissolve. To ensure that acceptor vesicles are not osmotically stressed during the exchange of lipid between the donors and acceptors, the acceptor LUVs are also prepared in a dilute salt solution (e.g., 20-30 mM NaCl) to balance the osmolarity of the mβCD solution. If it is necessary to prepare aLUVs in a higher-molarity buffer, appropriate tests (e.g., DLS) should be performed to ensure vesicle integrity.
Overall composition assay
The GC assay for quantifying liposome composition is sensitive to differences in the acyl chains (including isotopic differences) of the acceptor and donor lipids, as shown in Fig. 2c . If lipids with identical acyl chains are desired (e.g., POPC and POPE), TLC 19 or UHPLC 31 can be used instead of GC, as these techniques separate lipids based on chemical differences in their headgroups rather than their chains.
Asymmetry assay
Asymmetry assays are specific to lipid headgroups, and the 1 H NMR assay described below quantifies the inner/outer distribution of lipids with protiated choline headgroups (i.e., PC and SM). If an asymmetric bilayer composed of two different PC lipids is desired, it is possible to determine the transbilayer distribution of the lipids using NMR, provided that one of the lipids has a deuterated choline (as in the example used in the Procedure below). Other assays have been described that quantify the asymmetry of mixtures that do not contain any PC and SM lipids or that have a high concentration of charged lipids, for example, TNBS labeling of aminophospholipids 15 , oxidation or radiolabeling of exposed PG 13 , binding of a cationic peptide 10 , and zeta-potential measurements 32 .
Preparation of asymmetric proteoliposomes
If incorporation of a transmembrane protein into asymmetric liposomes is desired, the protein should be reconstituted into the acceptor vesicles. Additional control experiments should be performed to ensure that the presence of the protein does not interfere with the composition and asymmetry assays.
Preparation of cholesterol-containing aLUVs
If cholesterol-containing aLUVs are desired, the protocol should be modified by either (i) adding cholesterol to both the donor and the acceptor vesicles; (ii) introducing cholesterol after the preparation of phospholipid-only aLUVs, using cholesterol-loaded mβCD 35 ; or (iii) adding cholesterol to only the acceptor vesicles and optimizing the exchange conditions for the use of either hydroxypropyl-α-cyclodextrin 36 or methyl-α-cyclodextrin 37 (α-CDs can transport phospholipids but not cholesterol because of their smaller hydrophobic cavity). We note that determining the transbilayer distribution of cholesterol is not straightforward, as this molecule flip-flops rapidly between the two bilayer leaflets, making its extraction from, or selective labeling in, the outer leaflet inappropriate for quantification. 3 ). Store at −20°C for up to 1 year or at −80°C indefinitely. Lipids stored for longer than 1 year should be checked by TLC for impurities.
Methanolic HCl
In a fume hood, prepare methanolic HCl (1 M) by adding 3.04 mL of concentrated HCl to 30 mL of methanol in a beaker and then stirring to mix. Transfer the solution to a graduated cylinder and then add methanol to a total volume of 37 mL. Store the solution in a glass vial with a Teflon-lined cap at room temperature for up to 2 months 38 .
Methyl-β-cyclodextrin (35 mM)
Weigh the cyclodextrin powder in a volumetric flask (for 25 mL of solution, 1.1463 g of mβCD is needed). Add water until the flask is about half full, then cover the opening with foil and incubate at room temperature for 1-2 h or until the powder is fully dissolved. Bring the solution to the appropriate volume with water and mix by inverting the flask 20 times. The density of the solution should be 1.0114 g/cm 3 . The solution can be stored for a few days at room temperature or can be frozen at −20°C. If frozen, allow the frozen solution to warm to room temperature and gently mix it before use. c CRITICAL The solution can be safely kept for a few days on the bench, but freezing at −20°C is recommended for longer-term (up to 1 year) storage to prevent bacterial growth.
Equipment setup
Centrifugal filters Amicon filters contain trace amounts of glycerol that can interfere with NMR analysis. Before use, rinse the filters seven times by filling with 10 mL of ultrapure water and centrifuging at 5,000g for 2-5 min at 20°C. Fill the pre-rinsed filters with water and store at 4°C until use. 2 Using a glass syringe, transfer 205 μL (4.75 mg, 6.15 μmol lipid) of the POPC-d13 stock solution and 162 μL (0.25 mg, 0.324 μmol lipid) of the POPG stock solution to a glass scintillation vial (labeled 'acceptor'). c CRITICAL STEP Acceptor films are doped with 5 mol% POPG, a negatively charged lipid that has the same gel-to-fluid transition temperature as POPC, to ensure that all vesicles are unilamellar. Extrusion of lipid dispersions that contain only neutral lipids results in a non-negligible fraction of vesicles with two or more lamellae that are easily observed by small-angle X-ray scattering 39 . 3 Remove the organic solvent from the scintillation vials from Steps 1 and 2 with an inert gas stream and gentle heating, followed by overnight drying under high vacuum (~12 h). j PAUSE POINT Lipid films can be stored frozen for several months before hydration.
Preparation of acceptor unilamellar vesicles • Timing~2.5 h 4 Preheat the acceptor film from Step 2 to 40°C and hydrate it with 500 μL of preheated 25 mM NaCl solution to a lipid concentration of 10 mg/mL. Vortex the solution vigorously (i.e., at the highest setting) until the lipid film is completely removed from the walls of the vial. c CRITICAL STEP The temperature for hydration should always be greater than the melting temperature of the lipids. 5 Incubate the acceptor MLV suspension at 40°C for 1 h with occasional vortexing. 6 Transfer the acceptor MLV suspension to a −80°C freezer for~10 min or until completely frozen.
Thaw at 40°C for 5-10 min and then vortex. Repeat the freeze-thaw cycle five times. j PAUSE POINT MLV suspensions can be stored frozen for several months. Before use, a few freeze-thaw cycles should be performed. 7 To obtain unilamellar vesicles, pass the acceptor MLV suspension 31 times through a mini-extruder assembled with a 100-nm pore diameter polycarbonate filter. c CRITICAL STEP Extrusion should always be carried out at a temperature higher than the melting temperature of the lipids. Use a hot plate if needed and preheat the extruder before loading the lipid suspension. Then incubate for at least 10 min on the hot plate to equilibrate the temperature before extrusion. j PAUSE POINT Use immediately or store at room temperature for up to 1 week. 8 Measure the size distribution of the acceptor LUVs with DLS. Checking the size of the acceptors at this point is useful for diagnosing problems in the final aLUVs. ? TROUBLESHOOTING
Preparation of donor multilamellar vesicles • Timing~3 h
9 Preheat the donor film from Step 1 to 50°C and hydrate it with 775 μL of preheated 20% (wt/wt) sucrose to a lipid concentration of 20 mg/mL. Prepare an MLV suspension by vortexing the solution vigorously (i.e., at the highest setting) until the lipid film is completely removed from the walls of the vial. c CRITICAL STEP The temperature for hydration should always be above the melting temperature of the lipids. 10 Incubate the donor MLV suspension at 50°C for 1 h with occasional vigorous vortexing. 11 Transfer the donor MLV suspension to a −80°C freezer for~10 min or until completely frozen.
Thaw at 50°C for 5-10 min and then vortex. Repeat the freeze-thaw cycle five times. j PAUSE POINT MLV suspensions can be stored frozen for several months. Before use, a few freeze-thaw cycles should be performed. CRITICAL STEP To ensure efficient mixing during the next step, check that the level of the mβCD-donor solution is not much higher than the level of the stir bar. If the level is much higher, a larger beaker or other flat-bottom glass container can be used instead of the scintillation vial. 14 Incubate the mβCD-donor solution at room temperature with gentle stirring (~250 r.p.m.) for 2 h. c CRITICAL STEP Vigorous stirring can create foam, which may reduce the exchange efficiency. c CRITICAL STEP For optimal exchange efficiency, incubation should be performed at a temperature higher than the melting temperature of the acceptor lipids. c CRITICAL STEP Perform this step immediately before proceeding to the next step.
Incubation of acceptor vesicles with mβCD-donor solution • Timing~0.5 h
Add the acceptor LUVs from
Step 7 to the mβCD-donor solution and then incubate at room temperature with gentle stirring (~250 r.p.m.) for 30 min. c CRITICAL STEP We find little gain in exchange efficiency beyond 30 min for this lipid composition (M.D., F.A.H., and D.M., data not shown). c CRITICAL STEP For optimal exchange efficiency, the incubation should be performed at a temperature higher than the melting temperature of the acceptor lipids.
Purification of aLUVs • Timing~4 h
16 Measure the volume of the mβCD-donor-acceptor slurry and dilute it eightfold by adding~36 mL of ultrapure H 2 O. Transfer the mixture to a 50-mL conical tube and centrifuge at 20,000g for 30 min at 20°C. 17 Without disturbing the pellet, carefully remove the supernatant with a glass Pasteur pipette and transfer it to a clean 50-mL container. Discard the pellet. c CRITICAL STEP When a fixed-angle centrifuge rotor is used in Step 16, the pellet will form on the side wall of the centrifuge tube. Do not be overly aggressive when removing the supernatant. Keep the centrifuge tube immobilized on the bench and stop when~1 mL of supernatant remains above the topmost point of the pellet. 18 Transfer the supernatant to two 15-mL centrifugal filter devices. Centrifuge at 5,000g at 20°C until the volume has been reduced below 500 μL in each filter (~30 min). c CRITICAL STEP This step proceeds at a faster rate when using a swinging-bucket rotor, even at a lower speed (e.g., 2,500g). c CRITICAL STEP For larger-scale preparations, use additional centrifugal filters to reduce the time required to concentrate the supernatant. 22 Transfer 5-10 μL of the aLUV suspension (50-100 μg of lipid) to a 13×100-mm screw-top glass culture tube for conversion to fatty acid methyl esters (FAMEs) via acid-catalyzed methanolysis. c CRITICAL STEP The DLS count rates measured in Steps 8 and 21 can be used to estimate the aLUV concentration, which is helpful for determining the amount of sample required for the GC assay. 23 Add 1 mL of methanolic HCl to the culture tube, vortex, flush with Ar, and seal tightly with a Teflon-lined cap. Incubate in a dry block heater at 85°C for 1 h, and then allow the tube to cool for 5 min. 24 Add 1 mL of H 2 O and vortex to mix. Then add 1 mL of hexane and vortex vigorously (i.e., at the highest setting) for 15-30 s to create an emulsion and extract the FAMEs. c CRITICAL STEP Formation of the emulsion is visible to the eye as a rapid transition to a cloudy appearance of the vortexing solution. It may take several seconds for the emulsion to form. 25 Centrifuge at low speed (~400g) for 5 min at 20°C to break the emulsion, then remove 500-800 μL of the upper (hexane) phase and transfer it to a GC autosampler vial. Bring the total volume to 1 mL with hexane. 26 Load the autosampler vial into the GC's automatic liquid sampler. Using an inlet temperature of 270°C and helium carrier gas at a 1 mL/min flow rate, initiate the following column temperature program for a 1-μL sample aliquot in splitless injection mode (total run time = 25.5 min).
Step Total time (min) Rate (°C/min) Start temperature (°C) End temperature (°C)
27 GC/MSD ChemStation Enhanced Data Analysis software (Agilent Technologies) will assign and integrate the total ion chromatogram peaks. 28 Calculate the donor mole fraction (χ D ) in the aLUV sample:
where A d16:0 , A 16:0 , and A 18:1 are the integrated areas of the peaks corresponding to methyl palmitate-d31, methyl palmitate, and methyl oleate, respectively. Estimate the fraction of outer leaflet exchange (i.e., the exchange efficiency):
Note that this equation assumes negligible donor flip-flop and equal lipid packing density within the two leaflets. c CRITICAL STEP The accuracy of the determined composition can be increased with the use of a standard curve for the specific lipid mixture, as the area fractions may not vary linearly with the component mole fractions. 29 Compare E obs calculated in Step 28 with the maximum theoretical exchange efficiency, E max ¼ ρ=ðρ þ 0:5Þ, where ρ is the donor-to-acceptor ratio. For the 3:1 ratio used in this protocol, E max = 0.86. c CRITICAL STEP The equation for E max assumes that all donor lipid is available for exchange with the outer leaflet acceptor lipid, and that mβCD does not preferentially interact with either the donor or the acceptor lipid. E max therefore represents an upper limit of the exchange efficiency. Assuming negligible donor flip-flop during the exchange step, E obs > E max may indicate the presence of donor contamination. ? TROUBLESHOOTING Assessment of donor asymmetry with 1 H NMR • Timing~1 h 30 In a plastic snap-cap centrifuge tube, bring~50-100 μL of the aLUV suspension to 500 μL with D 2 O for a final lipid concentration of~0.5 mg/mL, then transfer it to a 5-mm NMR tube. 31 Load the sample into the NMR spectrometer and collect a standard 1 H pulse sequence with a 30°fl ip angle and 2-s delay time at 50°C. Collect 32-256 transients, depending on the signal-to-noise ratio. Locate the singlet resonance at~3.1-3.6 p.p.m. corresponding to the nine equivalent protons of the donor choline moiety (Fig. 3a) . Separate resonances may appear at~3.7 p.p.m., corresponding to residual mβCD in the sample. Broad peaks for the hydrocarbon acyl chains should be visible from~0.5 to 1.5 p.p.m. c CRITICAL STEP An asymmetric choline resonance may indicate contamination from SUVs, as shown in Fig. 3d . ? TROUBLESHOOTING 3+ /D 2 O solution directly into the NMR tube. Cap the tube and invert it a minimum of three times to mix the contents. Reload the sample in the NMR and collect 32-256 transients. All or part of the choline resonance will shift downfield (i.e., to a higher p.p.m. value) and broaden, as in Fig. 3b ; the shifted portion corresponds to protiated choline lipid (here, the donor lipid) located in the outer leaflet. Repeat this procedure a minimum of two to three times, or until a shift of at least 0.05 p.p.m. is achieved. 33 Export the NMR spectrum as an ASCII file, and then fit the resonances to Lorentzian functions (Fig. 3) . Two Lorentzian functions are used to model NMR data in the absence of Pr 3+ : one for the choline and one for the mβCD (if multiple mβCD peaks are present, each can be fit with a separate Lorentzian function). In the presence of Pr 3+ , a third Lorentzian function is used to account for the second (outer leaflet) choline resonance. To assist with the fitting routine, the peak area ratio between the choline and mβCD peaks in the absence of Pr 3+ can be used to constrain the area ratio of the total choline (i.e., the sum of the shifted and unshifted choline peaks) and mβCD in the presence of Pr 3+ , as neither choline nor mβCD are being lost from or added to the system. 34 Find the integrated areas R of the Lorentzian functions representing the shifted and unshifted (if present) choline resonances. Determine the fraction of donor lipid located in the outer leaflet, using the following equation:
Standard errors on f Fig. 3c . Although a gradual loss of asymmetry over several days will occur due to spontaneous lipid flip-flop, this process is slow for the specific sample described here when stored at room temperature (elevated temperatures will accelerate flip-flop 34 ). An initial absence of asymmetry, although not expected here, may occur for different choices of donor and acceptor lipids. The explanation may be trivial (i.e., an intrinsically fast flip-flop rate for the chosen composition) or it may indicate experimental conditions that are incompatible with aLUV preparation (i.e., an mβCD concentration that is too high for the chosen donor and acceptor lipids). 
The acceptor mole fractions in the outer and inner leaflets are then equal to 1 À χ 
Troubleshooting
Acceptor LUVs' size distribution is too large or too small (Step 8) Vesicles prepared by extrusion through 100-nm pores typically have size distributions centered at a 100-150-nm hydrodynamic diameter, as measured by DLS. If the acceptor vesicles are >150 nm in diameter, repeat Steps 7 and 8. Diameters much <100 nm may indicate that the extruder was accidentally assembled with a smaller-pore-size filter.
Donor pellet appears loose (Step 12)
A loose pellet is an indication that the donor MLVs are markedly heterogeneous in size and/or density, which may result in donor contamination in the final aLUV sample. Remove the diffuse parts of the pellet, along with the supernatant, and retain only that part of the pellet that adheres firmly to the walls of the centrifuge tube. 
Anticipated results
Beginners will need to perform several practice runs to obtain consistent results. Of note, the factors that influence mixing of the exchange slurry (e.g., temperature and stirring speed) in Steps 14 and 15 may influence the exchange efficiency, and careful removal of the supernatant in Step 17 is critical for avoiding contamination. With time and experience, aLUV compositional variation of <10% and a yield of >60% of the initial acceptor LUV mass can be achieved. If contamination of donor vesicles is present and additional dilution-concentration-wash steps are needed as outlined in the Troubleshooting section, the yield may be smaller.
For the specific lipid composition described above, the exchange efficiency, E obs , varies between 0.35 and 0.45 in our experience. If greater outer leaflet replacement is desired, the donor/acceptor ratio can be increased, or multiple rounds of exchange can be performed (keeping in mind that additional exchange steps will reduce the yield). Unsurprisingly, we find that exchange efficiency depends on the identity of both the donor and the acceptor lipids, with some systems approaching the maximum theoretical efficiency 22, 31, 34 . This is probably due to preferential interactions between mβCD and certain types of lipids that depend on both chain and headgroup structure 21, 40 . We find nearly complete donor asymmetry for this composition, with~95 mol% of DPPC-d62 residing in the outer leaflet, as determined by 1 H NMR. For other choices of donor and acceptor lipids, donor asymmetry measured immediately post preparation ranges from 65-95% 22, 31, 34 . Table 1 summarizes the aLUVs prepared in our laboratories.
Much can be learned about the fundamental physical and chemical properties of cell membranes using aLUVs. For example, it is possible to systematically study the nature and mechanisms of interleaflet coupling in vesicles that mimic the asymmetric lipid distribution found in the PM, including whether phase separation in one leaflet induces demixing of lipid components in the other leaflet. Such basic insights are necessary for understanding cellular processes, including transmembrane signaling. Using the Procedure described above, we prepared aLUVs having an outer leaflet composed of DPPC-d62/POPC-d13 in a 34:66 molar ratio and an inner leaflet composed of POPC-d13 (ref. 22 ). Using small-angle neutron scattering, we determined the structural parameters for the inner and the outer leaflets, including thickness and area per lipid. At room temperature, phase coexistence was observed in the outer leaflet of these aLUVs. Interestingly, we found a relatively low packing density for DPPC-d62 located in the outer leaflet compared with the typical tight packing of gel phases, suggesting a disordering effect from interactions with the fluid inner leaflet. This apparent strong interleaflet coupling was abolished at higher temperatures, at which both leaflets were in the disordered fluid phase 31 . Without question, asymmetric vesicles are better biological mimetics as compared with their symmetric counterparts that have dominated membrane biophysical studies for nearly 50 years. The tradeoff is ease of preparation, although we expect that substantial improvements will come with more widespread use of the procedures presented here and elsewhere 19 . Studies using aLUVs are still in their relative infancy, but it is already clear that asymmetry can substantially alter lipid lateral diffusion 41 , packing density 22 and phase behavior 42 , as well as the conformation 10 , partitioning 7 , and topology 8 of transmembrane proteins. Continued investigation will provide a deeper understanding of the properties of asymmetric bilayers and shed new light on the functional significance of membrane asymmetry in living cells.
Reporting Summary
Further information on experimental design is available in the Nature Research Reporting Summary linked to this article. 
Data exclusions
Describe any data exclusions. The sample prep was discarded if evidence of contamination was present. The identification of contamination is laid out in the manuscript as "Troubleshooting".
Replication
Describe whether the experimental findings were reliably reproduced.
Our prep is quite reproducible. Many of our studies required many sample to be prepared in order to assemble the proper kinetics data.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
N/A
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
N/A
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
